The UK research landscape in 2026
More than four million people in Britain live with type 2 diabetes, and research is moving faster than most patients realise. The most encouraging shift is not a single new drug but a change in how trials are run. Sites now span 141 towns and cities, according to the ClinicalTrials.gov registry, from Birmingham and Bristol to Blackpool and Newcastle, which means the old assumption that you have to live near London to take part no longer holds.
Take the recent NICE decision on weekly insulin. After trials showed that insulin efsitora alfa works as well as daily injections, the watchdog recommended NHS funding in England, opening the door for more than a million people to drop daily jabs. That decision came directly from clinical trial data, and it happened because people volunteered to test the treatment first.
Meanwhile, the NHS Path to Remission programme, known informally as the soups and shakes diet, keeps setting records. In the Midlands alone, more than 3,000 people enrolled in the last full year, double the figure from the year before, with average weight loss around 11% of body weight. None of that would be possible without the trials and service evaluations that keep refining the approach.
What the trials are actually testing
Type 2 diabetes: fewer injections and genuine remission
Type 2 diabetes trials in the UK fall into two broad camps. The first targets the way insulin is delivered. A phase 2 study run by Eli Lilly, recruiting at five UK cities, is comparing a new treatment against placebo in people already on a stable dose of semaglutide or tirzepatide. The aim is to see whether glucose control improves further without adding side effects.
The second camp is about remission rather than control. The NewDAWN trial, led by Oxford and Sheffield, is recruiting 1,788 people diagnosed with type 2 in the last six years who are willing to lose weight. Half get the standard Path to Remission offer, while the other half can choose from a wider menu of weight-loss programmes. The question is simple: does giving people more choice keep them engaged long enough to reach remission?
The West Midlands has become something of a proving ground here. Local figures show patient uptake doubling year on year, and clinicians point to better retention when programmes are adapted to local communities.
Type 1 diabetes: closing the loop at diagnosis
Type 1 research has moved on from measuring glucose to automating insulin. The CLOuD study is testing closed-loop insulin delivery in children and adolescents aged 10 to 18, starting within days of diagnosis. The theory is that tight control from the very beginning may preserve the beta cells that still produce some insulin, protecting against later complications.
Adults are covered too. The T1D-Plus study, run through Breakthrough T1D, is recruiting people aged 18 to 44 who have started insulin within the last six weeks. Participants attend a screening visit followed by six to eight visits over a year, and the data feeds into efforts to protect remaining beta-cell function.
Comparing the main options at a glance
| Trial or programme | Who it's for | What participation involves | Cost picture | Strengths | Things to weigh up |
|---|
| T1D-Plus (Breakthrough T1D) | Adults 18-44 recently diagnosed with type 1 | Screening plus 6-8 study visits over 12 months | Sponsor-funded with expenses covered | Focus on preserving beta cells early | Several hospital visits required |
| CLOuD closed-loop study | Children and adolescents 10-18 with new type 1 diagnosis | 12 months on closed-loop or standard therapy | Study technology provided | Access to advanced automated delivery | Tight eligibility window after diagnosis |
| NewDAWN weight-management trial | Adults with type 2 diagnosed in the last 6 years | Randomised to standard or wider weight-loss options | Programme costs covered by the study | Tests real-world remission at scale | Sustained dietary commitment over 12 months |
| Weekly insulin rollout (Onswik) | Adults with type 2 needing insulin | Once-weekly injection after NHS approval | NHS-funded treatment | Fewer daily injections for suitable patients | Not right for every insulin user |
The table skips exact price figures on purpose, because most research participation is covered by the sponsor or the NHS rather than billed to patients. What varies is the commitment, and that is worth thinking about before you sign up.
How to find a diabetes trial near you
Finding a suitable trial is easier than most people think. Start by raising it in your next diabetes review. Clinicians know which studies are open locally and whether you are likely to qualify, and they can flag ones you might otherwise miss.
From there, a few practical routes help:
- Search ClinicalTrials.gov and filter to UK sites. The registry is refreshed daily and lists recruiting status, sponsor and city.
- Use the trial finder at Breakthrough T1D for type 1 studies, which also runs an expression-of-interest form so you can be matched as sites open.
- Visit the NIHR Be Part of Research website, which gathers NHS studies across the country in plain language.
- Check your local hospital trust research page. Trusts like Berkshire Healthcare publish their current diabetes studies, including the Address 2 study for newly diagnosed people and their siblings.
Eligibility is decided by each study team, not by you alone, so do not rule yourself out based on a guess. The screening visit exists to answer those questions properly.
A realistic note on costs, safety and time
Every UK trial runs through ethics review before a single volunteer is recruited, and informed consent means you can withdraw at any point without explanation and without affecting your usual care. That last point matters, because some people worry that leaving a trial will harm their NHS treatment. It will not.
Travel is the main practical cost for most participants. Many studies reimburse expenses, and some run visits by phone or video, as with T1D-Plus. If time is the concern, start with a short survey-based study. Organisations like Breakthrough T1D run plenty of these, including one on diabetes burnout that takes about twenty minutes, and they help shape services without demanding clinic visits.
For weight management, the commitment is different. Remission trials ask for sustained dietary change, and the reward is potentially stepping away from medication under medical supervision. Anyone considering it should be honest about their schedule and the support they have at home before enrolling.
The quiet revolution happening in British clinics
What stands out about the current wave of UK trials is how ordinary the participants are. The person in the next bed, the teacher in Leeds, the retiree in the West Midlands, these are the people driving weekly insulin approvals and closed-loop rollouts. Anna, a 52-year-old teacher from Leeds, put it simply after joining a weight-management study: "I expected lab coats and complicated paperwork. Instead I got a clear plan and a team who checked in every month."
That is the reality for most volunteers now. The screening is thorough, the visits are scheduled around your life, and the payoff is knowledge about your own body that no annual check-up provides.
If the idea of joining a diabetes trial in the UK has crossed your mind, the cheapest first step is a conversation. Mention it at your next review, or browse the registries listed above and see what is recruiting near you. Research teams across Britain are waiting for exactly the kind of patient who reads this far: someone informed, curious and willing to help shape what diabetes care looks like next.
研究の知恵